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Abstract
The demographic structure of Latin American countries (LAC) is fast approaching that of
developing countries, and the predicted prevalence of dementia in the former already exceeds
the latter. Dementia has been declared a global challenge, yet regions around the world show
diﬀerences in both the nature and magnitude of such a challenge. This article provides evidence
and insights on barriers which, if overcome, would enable the harmonization of strategies to
tackle the dementia challenge in LAC. First, we analyze the lack of available epidemiologic data,
the need for standardizing clinical practice and improving physician training, and the existing
barriers regarding resources, culture, and stigmas. We discuss how these are preventing timely
care and research. Regarding speciﬁc health actions, most LAC have minimal mental health
facilities and do not have speciﬁc mental health policies or budgets speciﬁc to dementia. In
addition, local regulations may need to consider the regional context when developing treat-
ment and prevention strategies. The support needed nationally and internationally to enable
a smooth and timely transition of LAC to a position that integrates global strategies is high-
lighted. We focus on shared issues of poverty, cultural barriers, and socioeconomic vulnera-
bility. We identify avenues for collaboration aimed to study unique populations, improve valid
assessment methods, and generate opportunities for translational research, thus establishing
a regional network. The issues identiﬁed here point to future speciﬁc actions aimed at tackling
the dementia challenge in LAC.
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The call to ﬁght dementia has gone global.1 However, the
strategies, procedures, and tools to address this urgent issue
have not, with important barriers persisting in Latin
American countries (LAC) (see appendix e-1, S1, for
a deﬁnition of LAC, links.lww.com/WNL/A97). The de-
mographic structure of LAC is fast approaching that of
developing countries2 and the predicted prevalence of de-
mentia in the former already outreaches that in the latter.3
Although high variability among LAC exists, demographic
transition in this region is happening fast. In addition, fer-
tility rates and their relative decline have been uneven
across LAC (appendix e-l, S3). Yet understanding of the
factors relevant to dementia is currently limited,4 and a high
proportion of people with dementia in the region lack basic
support.5
The goal of this work
In this Perspective, we discuss the clinical and research
priorities necessary to enable harmonization of strategies to
tackle the dementia challenge in LAC. Regarding clinical
priorities, we discuss the current diagnostic procedures
(table 1), the need for improving physician training, and
factors aﬀecting timely diagnosis and care. We also consider
speciﬁc issues regarding mental health facilities and poli-
cies. Regarding research priorities, we highlight the lack of
epidemiologic data and the need for standardized di-
agnostic procedures. We also discuss the use of biomarkers
and the context of clinical trials in LAC. Finally, we propose
avenues for collaborations including dissemination forums,
research with unique populations, and opportunities for
a regional network for translational research. A consensus is
needed to enter the global dementia scenario with an ap-
pealing proposal that focuses on the harmonization of
actions across LAC in a way that captures global dementia
strategies.
The dementia challenge for LAC was recently highlighted
in the World Congress of Neurology meeting held in
Santiago, Chile.2 A group of experts from various LAC came
together to discuss concerns regarding barriers and
challenges in clinical research practice (appendix e-1, S2,
links.lww.com/WNL/A97). Four topics were addressed
and are discussed here: (1) timely diagnosis, (2) thera-
peutic approaches, (3) social and health support after
the diagnosis, and (4) potential avenues for collaboration
toward unmet needs. It was acknowledged by consensus
that such topics could trigger immediate actions
(table 2).
Timely diagnosis
Recent dementia recommendations stress the importance of
systematic and exhaustive clinical and cognitive investigations,
as well as biomarker approaches, to support both the timely
diagnosis of Alzheimer disease (AD)6 and prevention
initiatives.7,8 Whether such recommendations can be harmo-
nized across the developed and developing world is unclear at
present.Moreover, the potential beneﬁt of timely diagnosis and
the clinical utility of biomarkers has been questioned both at
the societal and individual level.9,10 Although the use of bio-
markers as diagnostic criteria oﬀers value in research settings,
concerns about the premature use of biomarkers in clinical
settings have been raised. Even if biomarkers are proven to be
accurate for diagnosis, the associated patient beneﬁt should be
considered, particularly in light of the cost of proposed bio-
markers and the necessary access to high-level equipment that
is currently unavailable in most LAC.11 The utility of bio-
markers is further questionable in low-income countries (LIC),
where the priority should be timely diagnosis using aﬀordable
neuropsychological and clinical assessments, and appropriate
patient care. Thus, the potential utility of biomarkers may be
predominantly in high-income countries (HIC) and to a lesser
degree in upper-middle-income countries (UMIC). Thus, the
use of biomarkers may represent a step toward better future
assessment predominantly in HIC,12 while care and clinical
assessment should be a priority in LIC and UMIC (see below).
There is a stringent limit to the budget available for research in
LIC and UMIC and the use of biomarkers would likely imply
a tradeoﬀ between quality of measurement and other desirable
features of research such as geographic, socioeconomic, and
racial diversity of sample participation as well as sample size,
response rates, and cost, to mention a few.
Challenges for LAC relevant to this call include the current
epidemiologic landscape, training of health care practitioners,
procedures followed to make a diagnosis, and factors aﬀecting
timely diagnosis.
Current epidemiologic landscape
From 2015 to 2050, the number of people with dementia in
LAC is predicted to increase 4-fold.3,13–15 By 2020, 89.28
million people with dementia will live in LMIC (in LAC:
Bolivia, el Salvador, Guatemala, Honduras, Nicaragua, Par-
aguay), relative to the 42.18 million living in HIC. In addi-
tion, UMIC, such as Argentina, Brazil, Chile, Costa Rica,
Cuba, Colombia, Dominican Republic, Ecuador, Mexico,
Peru, Uruguay, and Venezuela, will experience the greatest
Glossary
AD = Alzheimer disease; ADI = Alzheimer’s Disease International; AI = acetylcholinesterase inhibitors; HIC = high-income
countries; LAC = Latin American countries; LIC = low-income countries; UMIC = upper-middle-income countries.
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dementia impact.16 As is the case globally, the expected in-
crease in dementia in LAC is partly due to the aging
population.17,18 A combination of unsuitable diagnostic
procedures and low awareness has prevented accurate esti-
mates of dementia prevalence in LAC.19 TheWHO reported
a dementia prevalence of 5.5%–7% with a standardized
prevalence of 8.5%, although several LAC are un-
derrepresented in these statistics,16 and dementia prevalence
may be underestimated.20 Most reports rely on a limited
number of studies, which provide only a partial picture of the
problem in LAC.4 Thus, more rigorous epidemiologic
studies are required21 (table 3).
The Alzheimer’s Disease International (ADI) report14 in-
cluded ﬁgures from Cuba, Dominican Republic, Jamaica,
Peru, Venezuela, Mexico, Chile, and Brazil (14 publications).
Ethnic minorities in the United States reported prevalence of
dementia in Caribbean Hispanic Americans (12.2%) higher
than in Mexican Americans, Japanese Americans, and non-
Latino white populations.22 In fact, ADI reported the highest
Table 1 Diagnostic procedures followed by experts from the participating countries
LAC
Diagnostic workup: Steps to achieve
a diagnosis
Cognitive screening tests and
neuropsychiatric scales
Biomarkers
CSF
Amyloid/
tau-PET
FDG-
PET MRI EEG
Argentina The diagnosis is usually made by the GP
relying on the clinical history, laboratory tests,
and a CT scan. The GP rarely requests a full
neuropsychological assessment.
MMSE; ACE-R; IFS Yesa,c Yesa,c Yesa,c Yesa Yesb
Brazil Diagnosis is usually based on information of
cognitive decline provided by informants,
clinical examination, cognitive screening
tests, blood tests, and CT or MRI.
MMSE; MoCA; Brief Cognitive Screening
Battery
Yesa,c Yesa,c Yesb Yesa No
Caribbean The criterion validity of 10/66 diagnosis was
superior to that of DSM-IV.16
Community Screening Instrument for
Dementia, CERAD; cognitive test;
Geriatric Mental State; and structured
neurologic examination
Yesa,c Yesa,c Yesb Yesa No
Chile At the primary health level, people >65 years
undergo medical and functional examination
(EMPAN and EFAM). They can be either
referred to memory stimulation groups or to
secondary health care. This pathway is
available to approximately 40.3% of the
population at risk. At the secondary level,
diagnosis is based on neuropsychological
assessment, laboratory tests, and CT or MRI
scans.
EFAM includes an abbreviated version
of the MMSE, the Pfeffer Functional
Assessment Scale, and the evaluation
of the risk of falls; the Chilean version
of the ACE-R; The T-ADLQ; AD-8-Ch;
Picture and Verbal Version of the Free
and Cued Selective Reminding Test
No No Yesb Yesa No
Colombia The diagnosis relies on the clinical history
gathered from patient and family members,
neuropsychological assessment, brain
neuroimaging, and laboratory tests. Some
groups have implemented a genetic interview
(i.e., genealogy).
CERAD neuropsychological
battery, MoCA, and IFS
Yesb Yesb Yesb Yesa Yesb
Cuba The criterion validity of the 10/66 diagnosis
was superior to that of DSM-IV.16
Community Screening Instrument for
Dementia; CERAD; cognitive test;
Geriatric Mental State; and structured
neurologic examination
Yesa,c Yesa,c Yesb Yesa No
Mexico The criterion validity of the 10/66 diagnosis
was superior to that of DSM-IV.16
Community Screening Instrument for
Dementia; CERAD; cognitive test;
Geriatric Mental State; and structured
neurologic examination
Yesa,c Yesa,c Yesb Yesa No
Peru Three successive steps: screening, diagnosis,
and classification (i.e., dementia subtypes). All
patients with cognitive impairment identified
by the screening tests carry out the
evaluations proposed in steps 2 and 3.
Diagnosis is based on cognitive screening
tests, laboratory tests, and CT or MRI scans.
Screening phase: MMSE; the Clock
Drawing Test, Mano version; the
Pfeffer Functional Activities
Questionnaire; the Memory Alteration
Test; diagnosis phase: the Beck
Depression Index; ACE
No No Yes Yesa No
Abbreviations: ACE-R = Addenbrooke’s Cognitive Examination–revised; CERAD = Consortium to Establish a Registry for Alzheimer’s Disease; DSM-IV =
Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GP = general practitioner; IFS = INECO Frontal Screening; LAC = Latin American countries;
MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment.
In several LAC (e.g., Bolivia, Costa Rica, el Salvador, Panama, Paraguay,Uruguay),wewereunable to find sufficient evidence to include these countries in the table.
a Employed for clinical purposes.
bOnly for research purposes.
c Restricted to a few health institutions.
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global prevalence of dementia in LAC (8.4%) after North
Africa/Middle East (8.7%) in people >60 years.14 Variability
of dementia prevalence rates across LAC, however, is large
(ranging from 2% in Brazil23 to 13.7% in Venezuela,24 but
this has also been reported in some European countries25). It
has been suggested that such variability may result from dif-
ferences in methodologic procedures across studies (e.g., di-
agnostic criteria). Nevertheless, the crude estimated
prevalence of dementia in LAC in people >60 years (6.54%)
exceeds international prevalence (5.2%),16 demonstrating the
challenge ahead for LAC (table 3).
In countries such as Cuba, Dominican Republic, Mexico, and
Peru, dementia represents the largest contribution to dis-
ability.26 The Global Burden of Disease Study (2010) repor-
ted that dementia is also one of the key determinants of
disability and mortality in older people.5 In some LAC, de-
mentia leads to an increase in time disabled by over 200%, and
the number of deaths due to dementia has increased by 526%.
Moreover, higher rates of deaths among people with dementia
in hospital settings are observed in some LAC27: Cuba 41.4%;
Dominican Republic 29.1%; Peru (urban) 31.0%; Peru (rural)
83.3%; Mexico 31.3%. Notably, hospitalization is one of the
main health care cost factors in dementia.
Health care practitioners responsible
for the diagnosis of dementia
The diagnosis of dementia in LAC is usually made by a neu-
rologist, psychiatrist, or gerontologist, or on rare occasions, by
a general practitioner.28
Table 2 Actions toward a unified working agenda for Latin American countries (LAC)
Levels of action Issues Suggested strategies
Dissemination and
promoting a positive
dementia culture
Lack of motivation and confidence,
language barriers, or a combination of
these factors prevent timely and
accurate reporting of epidemiologic
data.
To establish a partnership with world leading organizations in the field. Support will be
sought toward effective strategies for dissemination and education of relevant
stakeholders (e.g., National Plan for Dementia in Chile).
New initiatives can be launched by higher education institutions of LAC to incentivize
and promote dissemination of scientific research in international peer-reviewed
journals.
General population Lack of awareness To generate a regional dementia strategy for LAC addressed to heads of government
and international agencies to raise awareness about specific factors delaying the
diagnosis of dementia and to make recommendations about feasible and affordable
strategies to overcome existing barriers including resources, culture, and stigmas.
To raise awareness through such a strategy on regional factors limiting participation of
LAC in worldwide dementia prevention initiatives (local policies, lack of registries).
To highlight the importance of setting upnational registries andbrain bank facilities and
linking them across LAC.
To promote a participatory culture in dementia research, which can be formed via
community groups, general practitioners, community nurses, or national media.
Health Lack of training To develop a regional training program for dementia. Such a program should address
the needs of different participants such as carers, nurses, social workers, general
practitioners, and other health professionals. Recommendations are made to
incorporate dementia training in the curriculum for undergraduate and postgraduate
programs.
To coordinate a pilot study to assess feasibility of telemedicine platforms to provide
support on issues prediagnosis and postdiagnosis. To this aim, LAC can rely on
colleagues fromUniversidad Central de Venezuela to explore avenues of collaboration.
Political Government and international support A systematic pursuit of support from national and international agencies. This will
include drafting an agenda for heads of governments aimed at raising awareness
among politicians of the status quo in the field of dementia in LAC.
Scientific Promote local exchange to maximize
resource utilization and access
The agenda will include (1) a LAC Congress on Dementia with regional journals
providing the dissemination forum; (2) the development of online platforms tomanage
registries of special populations, share data across LAC, and facilitate project
management as well as training; and (3) consolidation of a regional network for
translational neuroscience.
More regional discussion is needed among experts in the field to address issues such as
feasibility for LAC to adhere to international guidelines (e.g., table 1) or to developmore
specific regional guidelines.
Translation and
implementation
Capitalizing on existing infrastructures
and promoting interdisciplinary work
Establishment of a regional network for translational research and improved
assessment. This will include the implementation of IT platforms to share resources
such as access to regional brain banks, animal models, telecare infrastructure,
postdiagnosis support, training, and intervention programs.
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Access to diagnosis
Health facilities in LAC are predominantly located in large
cities, with a shortage of specialists in small towns and rural
areas. In Mexico, only 34% of the rural dementia population
receives support from the government16 and dementia health
care services are available to very few people.27 Moreover, in
most LAC, specialized services are covered by private health
insurance only. There are no primary health care programs to
address diagnosis or timely and adequate referral, and no
information is available about the process of referral, when
dementia is suspected. At the secondary health level, memory
clinics are very rare, although a few LAC provide dementia
diagnosis via dedicated research facilities.
Consensus criteria
In LAC, a limited number of private and public memory
clinics located in large cities provide services that meet in-
ternational consensus criteria and standards. The acceptance
of international recommendations on dementia by local
scientiﬁc/clinical/academic communities is increasing, but
does not receive systematic support from relevant stake-
holders. Such recommendations provide a framework for the
harmonization of diagnostic procedures, to identify individ-
uals transitioning to clinical AD.6 Table 1 summarizes how
current procedures in LAC map onto these recom-
mendations. Note that in LAC, adoption of these recom-
mendations is restricted to a few centers and does not
represent the typical scenario. Although eﬀorts are being
made to adhere to such procedures, they are far from ho-
mogenous. Interestingly, the use of neuroimaging markers
(e.g., amyloid/tau-PET and FDG-PET) appears to be more
consistent across LAC than cognitive assessment procedures.
Despite neuroimaging evidence heavily emphasized in current
international dementia recommendations,6 it is not clear how
feasible these practices are in LAC (see “Procedures followed
to make a diagnosis”).
Table 3 Epidemiologic studies in Latin American countries (LAC)
Country Study
Diagnostic
criteria Method, n/sampling/age
Prevalence
Crude Stand
Argentina Bartoloni et al., 2014e1 DSM-IV 1,795/Door-to door
population-based survey/
≥60
8.3
Brazil Herrera Jr et al., 2002e2 DSM-IV 1,656/Random/≥65 7.1 7.1
Ramos-Cerqueira et al., 2005e3 DSM-IV 2,222/Opportunistic/≥65 2.0
Chile Albala et al., 1997, reported by Nitrini et al., 2009e4 DSM-III-R and ICD-
10
2,213/Random/≥65 4.4 4.1
Fuentes et al., 2014e5 National Survey of
Dependencya
4,860/Rural and urban/≥60 7.0
Colombia Diaz Cabezas et al., 2013e6 Expert opiniona 317/Survey/≥65 6.0
Cuba Prince et al., 2015e7 DSM-IV 2,944/Urban/≥65 10.8 12.6
Llibre Rodriguez et al., 2005, reported by Nitrini et al., 2009,e4
also in Llibre Rodriguez et al., 2008e8
DSM-IV 18,351/Census and medical
registries/≥65
8.2 6.5
Dominican
Republic
Prince et al., 2015e7 DSM-IV 2,011/Urban/≥65 11.7 9.8
Mexico Prince et al., 2015e7 DSM-IV 1,002/Urban/≥65 8.6 7.4
Peru Custodio et al., 2007, reported by Nitrini et al., 2009e4 DSM-IV 1,532/Random/>65 6.72 6.7
Prince et al., 2015e7 DSM-IV 1,381/Urban/≥65 9.3 8.5
Uruguay Ketzoian et al., 1997, reported by Nitrini et al., 2009e4 Expert opiniona 2,731/Census/≥65 3.1 2.7
Venezuela Prince et al., 2015e7 DSM-IV 1,904/Urban/≥65 5.7 6.2
Maestre et al., 2002, reported by Nitrini et al., 2009e7 DSM-IV 1,360/Door-to-door survey/
≥65
13.7 12.2
Abbreviations: DSM-III-R = Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised; DSM-IV = Diagnostic and Statistical Manual of Mental
Disorders, 4th edition; ICD-10 = International Classification of Diseases–10; Stand = Standardized.
Epidemiologic studies reporting on the prevalence and incidence of dementia in LAC are still needed. Several existing reports have been published in
nonindexed Spanish journals, which are often not consulted when generating global statistics. Moreover, some LAC regions such as the Caribbean are
underrepresented (e.g., only Cuba and Dominican Republic have conducted epidemiologic studies). The high variability across reports, the low sample size,
and the underrepresentation of many countries calls for more rigorous and systematic epidemiologic studies. The table summarizes existing epidemiologic
findings in LAC, which reported dementia prevalence.
aNo consensus criteria reported. Note that in several LAC we were unable to find enough evidence to include these countries in the table (see e-references,
links.lww.com/WNL/A188).
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Training
There is an urgent need for training across diﬀerent levels of
the health care system, particularly at the primary care level.
Limited training and low conﬁdence of physicians contributes
to dementia underdiagnosis/misdiagnosis.28 A large pro-
portion of physicians in LAC have not received training re-
garding diﬀerential diagnosis and have limited knowledge
about the diﬀerent forms of dementia.28 Some training is of-
fered through relevant national societies, and some training
programs are available, but only for neurologists, geriatricians,
and psychiatrists. The general scenario demonstrates an ur-
gent need to incorporate education about dementia diagnosis
and management from undergraduate and postgraduate
programs through to continued education programs for
health practitioners, researchers, and social care workers.
Procedures followed to make
a diagnosis
Most LAC follow a basic 3-step clinical algorithm that com-
prises screening, diagnosis, and classiﬁcation (i.e., dementia
subtypes). Diagnosis is primarily based on clinical information
and detailed cognitive assessments are primarily available in
private institutions only (table 1). Availability of imaging and
biomarkers is restricted to a few centers. For instance, in
Argentina, a few institutions have incorporated AD
biomarkers as part of international protocols (e.g., the
Alzheimer’s Disease Neuroimaging Initiative). Genetic
screening is rare with some exceptions (i.e., Colombia and
Argentina, not at a national level, but focused on a few
centers). The Neuroscience Group of Antioquia has imple-
mented a genetic interview to investigate family inheritance of
neurologic diseases. This approach has been key to revealing
an unprecedented geographic clustering of neurodegenerative
genetic diseases in that country.
Basic recommendations and guidelines for dementia di-
agnosis are available in a subset of LAC only (e.g., Chile,
Argentina, Mexico, and Brazil).16,27 In Chile, the Ministry of
Health launched guidelines for primary care and a Chilean
Society has launched guidelines for specialists. In Argentina,
the ﬁrst Clinical Practice Guidelines have been reported, while
the Brazilian Academy of Neurology has made recom-
mendations on diagnostic criteria, screening, neuro-
psychological evaluation, blood tests, and neuroimaging.
However, a much broader health approach as recently
launched in HIC16 is required. Thus, although there is local
awareness in some countries regarding the importance of
harmonizing diagnostic procedures, this awareness has not
reached a regional level (i.e., LAC). Moreover, multiple
factors such as resources, culture, language, and stigmas aﬀect
the accurate diagnosis (table 4).
Therapeutic approaches
Experience running international or local clinical trials in LAC
is mixed. A small amount of drug trials reported worldwide
have included LAC, with diﬀerences among countries. This
region oﬀers an appealing environment for dementia research,
although more regional integration is required (table 4). The
regional experience lacks systematic organization and regional
registries. In some cases, strong bias and negative stereotypes
about medication have been observed.
Local regulations
An important factor limiting participation of LAC in in-
ternational clinical trials is the position of relevant ethics
committees, which until recently have had strong reservations
about clinical trials in developing countries, even when they
are part of international initiatives. However, there are
Table 4 Regional experiencea
Clinical trials Of the 715 intervention studies reported worldwide, only 51 included LAC (Chile: 20, Argentina: 17, Brazil: 8, Peru: 4, Colombia: 1,
and Venezuela: 1).e9–10Moreover, of the 363 current AD drug trials, only 2 involved LAC. Trials of gantenerumab in prodromal AD
are underway in Brazil, Argentina, and Chile. Trials of solanezumab in AD are ongoing in Brazil and Argentina. In Peru, in the last 2
years, trials of masitinib and gantenerumab have been rejected by the National Health Institute. In contrast, the Neuroscience
Group from Antioquia, Colombia, is currently running one of the largest prevention trials involving asymptomatic PSEN1 gene
mutation carriers (API Colombia programe10).
Unique conditions LAC offer a unique and appealing environment for drug research, given the combination of large populations living in large cities
together with the presence of rare conditions such as clusters of autosomal dominant variants of neurodegenerative diseases
causing AD, vascular dementia, frontotemporal dementia, and Huntington disease.e9–12 Such population characteristics enable
accelerated enrollment, high recruitment levels, high retention rates, and simplified follow-up algorithms. These factors can
dramatically improve trial efficiency, adherence to tight timelines, and resource optimization.
Absent regional
regulation
The lack of regional registries for clinical trials poses important restrictions for LAC. No systematic information regarding the
effect of clinical trials on highly vulnerable populations exists (e.g., exposed to poverty, violence, low education, and other types of
social deprivation). Moreover, some dementia subtypes are underinvestigated (e.g., Huntington disease, cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalopathy, and Parkinson disease).
Regional brain banks Some LAC countries such as Brazil, Argentina, and Colombia have fully functional brain bank facilities. While regional groups are
keen to facilitate collaborative research with other countries, more collaborative work is required.
Abbreviations: AD = Alzheimer disease; LAC = Latin American countries.
a See e-references, links.lww.com/WNL/A188.
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encouraging examples in the region, including a landmark
prevention trial in familial AD in Columbia.7,29 Some LAC
have government regulations that pose challenges to clinical
trials. For instance, in Chile, a new law on patients’ rights and
duties imposes several restrictions. Article 23 of the law 20584
prohibits the participation of vulnerable people in scientiﬁc
research studies who are unable to provide consent. This has
caused concerns among ethics committees, which have had to
reject applications based on such legislation, aﬀecting
researchers as well as people with dementia. Also, most
research is supported by industry, with academic trials rep-
resenting a small proportion of research and involving small
sample sizes (although this does not seem to be speciﬁc to
LAC). The implications of this pattern for the direction of
research as well as the validity and availability of results merits
attention in future works. Finally, no regional guidelines for
multicountry clinical trials exist. Thus, some local regulations
may need to be revised to reﬂect global dementia strategies.
Currently available treatments
Unlike many HIC (e.g., United Kingdom, France, Norway,
United States, and South Korea) where governments have
developed speciﬁc dementia plans or strategies, most LAC
have minimal mental health facilities with no speciﬁc policies
or budgets for mental health.15Currently available treatments,
research opportunities, and clinical assessment of dementia
appears to depend on a country’s political stability and eco-
nomic capacity16,30–32 (appendix e-1, S6, links.lww.com/
WNL/A97).
In Chile, as in many other LAC, care is mostly delivered by
family relatives, with most of the cost of dementia accounted
for by informal care.16 Availability of pharmaceuticals for de-
mentia across LAC is variable, with the exception of Mexico,
where the cost of dementia medications is much lower than in
other LMIC.27 In Colombia and Peru, only private health
insurance companies provide acetylcholinesterase inhibitors
(AI) or glutamate modulators. In Chile, the public health
system delivers pharmaceutical treatment for neuropsychiat-
ric symptoms of dementia, but does not cover speciﬁc treat-
ments for dementia subtypes. The Brazilian government
supports treatment with AI for AD; however, respite facilities
or nursing home access are not supported. In Argentina, AI,
Souvenaid, and Cerebolysin are supported by the public
health system. Moreover, patients with dementia have access
to a national certiﬁcate of disability, which allows them access
to full medical coverage. In general, memory enhancers are
diﬃcult to obtain. Moreover, nonpharmacologic treatments,
as well as social and health support postdiagnosis, pose similar
challenges in LAC (tables 5 and 6).
Nonpharmacologic approaches may oﬀer an attractive alter-
native for LAC. At the Alzheimer’s Association International
Conference 2016, evidence on cognitive intervention pro-
grams using information technology was presented. Such
approaches have shown relevant improvements in cognitive
functions, transfer across cognitive domains, and enhanced
functioning in randomized controlled trials. Interestingly,
these eﬀects appear to persist to some extent for at least 5
years.33 More recently, the Finnish Geriatric Intervention
Study to Prevent Cognitive Impairment and Disability
Table 5 Factors affecting timely diagnosisa
The private/public
divide
The private/public divide determines the quality and promptness of diagnosis, the length of waiting lists, and the proportion of
people who can access health care facilities. Intervention programs in Argentina, Chile, Dominican Republic, Mexico, Peru, and
Venezuela showed larger effects on caregiver psychological morbidity and burden than in HIC.e13 There are no centers of
excellence at a public level. This lack of access, together with socioeconomic inequalities, highlights the importance of identifying
actions that can address these urgent needs.e14
Cultural differences More than 400 different indigenous groups are estimated to live within LAC,e15 and around 89% of them live in Bolivia, Guatemala,
Peru, Ecuador, andMexico, which have 5–13million indigenous citizens each.e16 InMexico, 16%of the population is indigenous and
this population is facing major difficulties accessing dementia care.e17Moreover, illiteracy and low education are major problems
affecting most LACe18–e19 (the illiteracy rate in the older population is approximately 10%e20). Even high levels of food insecurity
have been observed in the Dominican Republic, Mexico, and Perue13 in people with dementia. The extent to which these
sociocultural factors influence dementia prevalence in LAC needs to be investigated.
Language
differences
LAC are not homogenous in terms of language (e.g., ethnic minorities and indigenous groups with specific communication
systems). Several countries have indigenous populations who speak non-Spanish native languages. Most tests used for the
detection of cognitive impairments have been adapted and translated from different cultural backgrounds.e18–e19 Thus, there is
a need for culturally unbiased language-free approaches to assess these populations. Although there have been a few attempts to
tackle this issue (see reference e21), the basis of cultural effects is poorly understood. Normative data are likely not generalizable
across different populationse22 and can influence dementia misdiagnosis.e23
Stigma LAC with more education and improved health facilities have better dementia diagnosis and outcome.e24 For example, according
to experts from Colombia, families affected by the gene mutation (familial AD) believe the disease is a deterministic, natural
condition and thus do not hope for any solution from the health system. In Chile, negative stigma is observed in members of the
Mapuche community, which has a high prevalence of dementia. In Mexico (as in many other LAC), low levels of awareness
contribute to low rates of diagnosis.e17 Some families are reticent to disclose the diagnosis to affected relatives. Indeed, stigma has
been recognized as amajor factor preventing the implementation of effective dementia strategies not only in LAC, but around the
world.e25 Thus, stigma and myths associated with the diagnosis of dementia are important in LAC and require specific actions.
Abbreviations: AD = Alzheimer disease; HIC = high-income countries; LAC = Latin American countries.
a Resources, culture, language, and stigmas are common factors influencing the dementia diagnosis across the worlde13 and particularly in LAC. See
e-references, links.lww.com/WNL/A188.
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(FINGER) study has combined comprehensive intervention
with technology to enhance cognitive functions.34 The use of
technology has become common practice among older peo-
ple from LAC. Some researchers have started to investigate
whether this social trend could oﬀer new opportunities to
assess functioning in those at risk of dementia.35Nevertheless,
we acknowledge that though promising, this area is in its
infancy and more work will be needed before it can be in-
troduced into clinical practice.
Potential avenues for collaboration
Even at a global level, comprehensive dementia health care
cannot be aﬀorded by existing care models.27 The potential of
LAC to tackle important priorities in dementia research is
unanimously acknowledged by this expert panel.
Promoting collaboration forums and
large-scale computational capacity
One option for LAC is to establish an agenda to organize
meetings in diﬀerent countries, which could create opportu-
nities for researchers to discuss local work and increase sci-
entiﬁc debate and interactions (appendix e-1, S4, links.lww.
com/WNL/A97). Secondly, the development of large-scale
computational capacity (e.g., Linux clusters) would oﬀer
a platform for intensive dementia research, screening pro-
grams, and big data analysis (appendix e-1, S4).
Capitalizing on unique populations
LAC oﬀer access to unique populations (genetic clusters, low
literacy, multilingual, multiethnic).36 This region hosts the
world’s largest populations of familial AD (Colombia), Hun-
tington disease (Venezuela), and ataxia (Cuba), alongside
multiple novel and rare functional genomic variants of other
diseases. For instance, the Caribbean has a high late-onset
dementia incidence, and genetic studies have shown large eﬀect
sizes.37 These unique genetic presentations can be exploited at
a regional level. Moreover, the socioeconomic status of several
communities provides a natural scenario to study the role of
vulnerability, resilience, and gene–environment interactions,
such as in the blue zones. Multilingualism is another important
factor that can be studied. Many LAC are suitable for studying
bilingualism and its inﬂuence on cognitive reserve in situ. In
LAC, it is possible to ﬁnd people who are illiterate, but still
functioning at a relatively normal level within their community.
In Mexico, Peru, Cuba, and Dominican Republic, education
and literacy seems to protect against dementia onset.20
Studying these populations may help to disentangle the eﬀects
of education and other social factors. Finally, the development
of robust cognitive neuroscience methods to tackle dementia
research are now emerging in the region.38–51 However, the
need for more research at a global level is necessary27 and LAC
should be integrated into this pathway.
The unique conditions found in LAC could inform causal
inference by etiologic triangulation.52 This triangulation
from diﬀerent approaches and measures can unveil key
sources of potential bias. Combining diﬀerent regional
approaches (within LAC and among LAC and other
regions) with studies at diﬀerent levels (genetic, cognitive,
neuronal, epidemiologic), which are available to researchers
globally at a modest cost, will represent a novel advance in
the ﬁeld of dementia.
Toward a regional network for
translation research
Several LAC are currently working with animal models.
Examples include the Neuroscience Group of Antioquia,
Table 6 Social and health support after diagnosisa
Models of care Models of care from developed countries may not be suitable to implement in LAC without important modifications, given
socioeconomic and sociocultural differences, especially in LMIC,e13 where resources are limited. There is a lack of explicit care
schemes in many LAC.e17 Although dementia has emerged as the leading single chronic disease contributor to dependence in
people >65 years in many LAC,e26 governments are not yet fully aware of the magnitude of the problem.
Family support Family support remains the main pillar for patients after dementia diagnosis; however, adequate networking between affected
families or with extended social groups is limited. Furthermore, families cannot support the cost of interventions in continuously
changing conditions.e27 This represents a serious problem given the reduced survival in individuals embedded in restricted social
networks.e28 This problem is further exacerbated in LIC where poverty is common and makes patients particularly vulnerable.
Although care is sometimes divided among several family members, one individual typically provides the majority of care,e13,e29
which usually leads to increased carer burdene29 (see appendix e-1, S6, links.lww.com/WNL/A97).
Additional LAC
constraints
The number of physicians per affected individual is variable between countries, as well as the proportion of private and public
organizations. The distribution of resources is unequal and those less advantaged have very little or no social support (with Cuba
as an exceptione-13). In most LAC, there are no national social programs, but private, academic, religious, philanthropic, and
industry-based local programs exist.e-13,17 Aware of this challenge, some LAC have started to implement initiatives to support
affected families; for example, ALMA in Argentina, “No me olvides” in Colombia, CIAM in Peru, and the Brazilian Federation of
Alzheimer’s Associations. Such initiatives could be strengthened and expanded by incorporating IT platforms such as
telemedicine (e.g., Venezuela telemedicine program). Issues such as lack of Internet access or electricity in most of the rural
regions of LAC, however, will need to be addressed firste27 (see also appendix e-1, S6, links.lww.com/WNL/A97).
Abbreviations: LAC = Latin American countries; LIC = low-income countries.
a See e-references, links.lww.com/WNL/A188.
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Colombia; the Federal University of Rio de Janeiro, Brazil;
the Max Planck Institute and the Institute of Cognitive and
Translational Neuroscience in Argentina; the Geroscience
Center for Brain Health and Metabolism; and the
Fraunhofer Institute from Chile. Advances are being made
by studying species such as the Octodon degus, an endemic
rodent from Chile that spontaneously develops an analogue
of dementia.53 The use of low-cost accessible technologies
such as inexpensive cognitive screening tools that are cul-
turally unbiased54 as well as additional measures such as
high-density, portable, and even basic EEG40,45,55,56 may
provide aﬀordable improved assessment solutions in the
short term. Standardization of collection and measurement
is necessary to take advantage of clinical developments,
imaging, biomarkers, and clinical trials.12 It is time to do this
at the LAC network level.
Discussion
The key aim of this article was to identify areas of priority on
which LAC should focus, to join global research on dementia,
and to harmonize clinical and research practices in-
ternationally. We have provided evidence indicating that such
harmonization may need to be preceded by regional solutions
to address the most imminent priorities (appendix e-1, S5,
links.lww.com/WNL/A97).
We have identiﬁed regional gaps and strategies. Core gaps
include (1) limited reliable epidemiologic data, (2) lack of
a LAC dementia strategy encouraging governments to set
speciﬁc mental health policies and budgets, (3) lack of cul-
turally valid assessment procedures and reliable diagnostic
markers that enable comparison of dementia ﬁgures among
LAC and internationally, and (4) lack of a uniﬁed LAC
agenda to facilitate collaboration and rapid translation of
research ﬁndings in the region (tables 2 and 3 for details).
Strategies to tackle these regional needs were also identiﬁed.
These include (1) dissemination aimed at increasing outputs
in scientiﬁc outlets, educational materials, and social media;
(2) an integration agenda aimed at increasing opportunities
for scientiﬁc debate and interactions, professional training,
knowledge and resource exchanges, and shared IT in-
frastructure; and (3) a political agenda targeting relevant
stakeholders, policy makers, government agencies, and in-
ternational organizations to raise awareness of LAC chal-
lenges and support harmonization of strategies globally
(table 2). Several unresolved issues will require joint eﬀorts
between LAC. Certainly, this is not a comprehensive treat-
ment of all relevant issues. For instance, prevention and
prevention research are important topics outside the scope of
the article that should be assessed in future works. It is not
entirely clear whether and how models of diagnosis and care
from developed countries can be implemented, at least at
present, in LAC. Given socioeconomic and sociocultural
diﬀerences, we anticipate that critical modiﬁcations will be
necessary.
For instance, all these topics presented above could trigger
immediate actions:
c There is a need for scientiﬁcally rigorous regional
epidemiologic studies that systematically investigate
prevalence, incidence, resilience, and cognitive reserve.
c LAC need a national and a regional dementia strategy.
Such strategy should be aimed at heads of governments
and international agencies to encourage more regional
collaboration.
c Support will be needed from national/international
organizations to enable a smooth and timely transition
of LAC from their current status to a position that best
captures global strategies.
c More collaboration between LAC is urgently needed,
including (1) promoting new regional collaboration
forums; (2) capitalizing on unique populations; (3)
working toward a regional network for translational
research and assessment; and (4) developing LAC
dementia registries to accelerate research discoveries.
We envisage that this opinion article will pave the way
toward a LAC working agenda that will harness the sup-
port needed both to provide better care for people with
dementia and to facilitate the translation of research
developments into local solutions that meet global
standards.
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